Literature DB >> 15761916

Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.

Xavière Panhard1, France Mentré.   

Abstract

We propose tests based on non-linear mixed effects models (NLMEM) in pharmacokinetic interaction and bioequivalence cross-over trials comparing two treatments or two formulations. To compare the logarithm of the area under the curve (AUC) using these models, two approaches are studied: in the first one, concentration data are analysed globally, with and without the estimation of a treatment effect; and in the second one, they are analysed separately in each treatment group with the estimation of the individual parameters. Four tests for comparison of the logarithm AUC between two treatment arms are studied: a likelihood-ratio test (LRT), a Wald test and two tests, parametric and non-parametric, comparing the individual Empirical Bayes (EB) estimates. These tests are adapted to the case of equivalence, except the LRT which does not have any simple extension. We evaluate by simulation of the type I error and the power for both comparison and equivalence tests. They are compared to the standard tests recommended by the FDA and the EMEA, based on non-compartmental (NC) AUC. Trials for a usual PK model are simulated under H(0) and several H(1) using S-plus software and analysed with the nlme function. Different configurations of the number of subjects (n=12, 24 and 40) and of the number of samples per subject (J=10, 5 and 3) are studied. The type I error alpha of LRT and Wald comparison test in the 5000 replications of interaction cross-over trials is found to be 20.9 per cent and 21.7 per cent, respectively, in the original design (n=12, J=10), which is far superior to 5 per cent, and decreases when n increases. When n is fixed, alpha is found to increase with J. Power is satisfactory for both tests, after correction of the significance threshold. Results of EB and NC tests are similar with satisfactory powers and a type I error close to 5 per cent, except when J=3 for EB tests. Similar results are obtained for equivalence tests, except for EB and NC Student tests, which are not of a great interest. NC tests keep their place when the number of samples per subject J is large, but NLMEM seem useful for cross-over studies performed in special populations where J limited; the evaluation by Monte-Carlo simulations of empirical threshold seems however necessary because of the inflation of the type I error.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761916     DOI: 10.1002/sim.2047

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  14 in total

1.  Norfloxacin blood-brain barrier transport in rats is not affected by probenecid coadministration.

Authors:  Sandrine Marchand; Anna Forsell; Marylore Chenel; Emmanuelle Comets; Isabelle Lamarche; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Authors:  Julie Bertrand; Emmanuelle Comets; France Mentre
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

3.  Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

Authors:  A Dubois; S Gsteiger; S Balser; E Pigeolet; J L Steimer; G Pillai; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

4.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

5.  Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.

Authors:  Xavière Panhard; Adeline Samson
Journal:  Biostatistics       Date:  2008-06-25       Impact factor: 5.899

6.  Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.

Authors:  Anne Dubois; Sandro Gsteiger; Etienne Pigeolet; France Mentré
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

7.  Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations.

Authors:  Jim H Hughes; Richard N Upton; David J R Foster
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-13       Impact factor: 2.745

8.  Novel Approach for the Bioequivalence Assessment of Topical Cream Formulations: Model-Based Analysis of Tape Stripping Data Correctly Concludes BE and BIE.

Authors:  Deniz Ozdin; Isadore Kanfer; Murray P Ducharme
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

9.  Design and inference for 3-stage bioequivalence testing with serial sampling data.

Authors:  Fangrong Yan; Huihong Zhu; Junlin Liu; Liyun Jiang; Xuelin Huang
Journal:  Pharm Stat       Date:  2018-05-03       Impact factor: 1.894

10.  A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.

Authors:  Xavier Delavenne; Edouard Ollier; Thierry Basset; Laurent Bertoletti; Sandrine Accassat; Arnauld Garcin; Silvy Laporte; Paul Zufferey; Patrick Mismetti
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.